Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Observer-blind, Randomized, Placebo-controlled Multi-country Study to Assess Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age
Conditions
Interventions
NgG low dose investigational vaccine
NgG medium dose investigational vaccine
+4 more
Locations
23
United States
GSK Investigational Site
Washington D.C., District of Columbia, United States
GSK Investigational Site
Lenexa, Kansas, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Springfield, Missouri, United States
GSK Investigational Site
The Bronx, New York, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
Start Date
November 28, 2022
Primary Completion Date
May 22, 2025
Completion Date
May 22, 2025
Last Updated
August 7, 2025
NCT05398185
NCT07072481
NCT06579781
NCT06188442
NCT06007534
NCT04762134
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions